Merck & Co out-licences clinical-stage gene therapy asset to new start-up

A new Finnish company has been set up to develop a gene therapy licensed from Merck & Co. FKD Therapeutics is being led by the former CEO of Ark Therapeutics, which stumbled at the final regulatory hurdle with Cerepro, a gene therapy candidate for brain cancer (scripintelligence.com, 21 December 2009).

A new Finnish company has been set up to develop a gene therapy licensed from Merck & Co. FKD Therapeutics is being led by the former CEO of Ark Therapeutics, which stumbled at the final regulatory hurdle with Cerepro, a gene therapy candidate for brain cancer (scripintelligence.com, 21 December 2009).

Under their agreement, Merck has granted FKD an exclusive licence to develop and commercialise a recombinant adenoviral interferon alfa 2b...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category